ReviewMycopathologia2018
Azole Resistance in Aspergillus fumigatus in Patients with Cystic Fibrosis: A Matter of Concern?
Review in Mycopathologia, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 45 citations in OpenAlex.
- Global epidemiology of azole resistance inJAC-antimicrobial resistance · 2026Review
- Fungal Colonization of the Airways of Patients with Cystic Fibrosis: the Role of the Environmental Reservoirs.Mycopathologia · 2024Review
- The Molecular Identification and Antifungal Susceptibility of Clinical Isolates ofMicroorganisms · 2023Article
- Real-world efficacy of anti-IL-5 treatment in patients with allergic bronchopulmonary aspergillosis.Scientific reports · 2023Article
- Synergy BetweenFrontiers in cellular and infection microbiology · 2022Article
- Emerging Fungal Threats in Cystic Fibrosis.Mycopathologia · 2021Review
- Article
- Review
- Managing Fungal Infections in Cystic Fibrosis Patients: Challenges in Clinical Practice.Infection and drug resistance · 2021Review
- Azole Resistance inFrontiers in cellular and infection microbiology · 2020Article
- Azole-ResistantFrontiers in microbiology · 2020Article
- Aerosol Transmission of Aspergillus fumigatus in Cystic Fibrosis Patients in the Netherlands.Emerging infectious diseases · 2019Article
- Relevance of heterokaryosis for adaptation and azole-resistance development in Aspergillus fumigatus.Proceedings. Biological sciences · 2019Article
- Respiratory Fungal Diseases in Adult Patients With Cystic Fibrosis.Clinical medicine insights. Circulatory, respiratory and pulmonary medicine · 2019Review
- Determination of Azole Resistance and TRMycopathologia · 2018Article
- Evaluation of the Antifungal Activity of the Novel Oral Glucan Synthase Inhibitor SCY-078, Singly and in Combination, for the Treatment of Invasive Aspergillosis.Antimicrobial agents and chemotherapy · 2018Article
- Fungal Respiratory Infections in Cystic Fibrosis (CF): Recent Progress and Future Research Agenda.Mycopathologia · 2018Article
- Performance of Molecular Approaches forFrontiers in microbiology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aspergillus fumigatus is the most frequent filamentous fungus isolated from respiratory specimens from patients with cystic fibrosis (CF). Triazoles are the most widely used antifungals in the treatment of allergic bronchopulmonary aspergillosis (ABPA) and invasive aspergillosis (IA) in CF patients. Treatment success could be severely compromised by the occurrence of azole-resistant A. fumigatus (ARAf), which is increasingly reported worldwide from both clinical samples and the environment. In previous studies, ARAf has been detected in up to 8% of CF patients. Isolates from CF patients requiring antifungal treatment should therefore be routinely subjected to antifungal susceptibility testing. The optimal treatment of ABPA or IA in CF patients with azole-resistant isolates has not been established; treatment options include liposomal amphotericin B i.v. and/or echinocandins i.v.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.